Infiltration of sarcoid granuloma in old cutaneous scars is one of the uncommon cutaneous manifestations of sarcoidosis. Here, we report the case of a 32-year-old female who presented with pain and swelling in 9 month old appendicectomy scar. An incisional scar biopsy revealed granuloma. On query she had inflammatory polyarthritis and persistant dry cough for last 2 months. High-Resolution CT (HRCT) revealed right paratracheal, both hilar, paraaortic and subcarinal lymphadenopathy with pulmonary nodular densities in both lung fields. FNAC from mediastinal node revealed non caseating granuloma consistent with Sarcoidosis. Successful regression of cutaneous inflammation was achieved using a course of oral steroids, hydroxychloroquine and methotrxate. The onset of scar sarcoidosis is rare and, therefore, not well understood; however, inflammatory alterations in preexisting scars may be important indicators for disease onset.

There are different methods to detect three-dimensional motions in biomechanical testing. Optical motion analysis or ultrasound-based systems seem to be the gold standard and have been described in previous studies. However, measuring the three-dimensional motion of a complex structure such as the lumbar spine is still challenging. With the current study, we introduce a new method to measure and at the same time to visualise the complex three-dimensional motion of the lumbar spine. It is a model-based tracking technique. We matched the three-dimensional motion of a lumbar spine with an optical motion analysis system. This was conducted in a spine testing machine with a 3D reconstruction from a CT scan. This method allows for visualization of the in vitro recorded motion of a lumbar spine using a normal CT dataset. Furthermore, the motion of the lumbar spine could be analysed in areas that were not seen by the two cameras of the optical motion tracking system. This method facilitates future research of the locomotor system using complex motion analysis in biomechanical testing.

Methotrexate (MTX) is used as a DMARDs for some autoimmune illnesses, inclusive of rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis and plenty of sorts of vacuities. Low-dose, weekly MTX (10 to 25 mg/week) used as both monotherapy or in mixture with other drugs, has an advanced efficacy profile as defined in placebo-managed trials and comparable efficacy to different medicines which include anti-TNF remedy. Patients suffering from rheumatoid arthritis (RA) may have some comorbid conditions that require a combination of a lot of medicinal drugs. For these comorbidities, prescription show polypharmacy and these medicines may additionally regulate the efficacy or growth of the toxicity of methotrexate (MTX). Interactions among drugs (DDIs) among the prescribed drugs are the reason behind the ADRs and these adverse effects are commonly seen in the aged patients (above 65) due to poly-pharmacy in prescription. In truth, poly-therapy boom the complexity of the therapeutic management and thereby the risk of a clinically applicable drug interaction. In this review, we report the interactions between MTX and the other tablets commonly used in the control of rheumatoid arthritis. The usage of google scholar, PubMed, PCM, NCBI website and reference lists. we studied the study material posted until 2019 and file the most common drugdrug interaction founds in the prescription of RA patients treating with MTX. In the context of a cure for MTX and NSAIDs like COX-1, COX-2 inhibitor, and among glucocorticoids or immunosuppressive medicinal products e.g., azathioprine, and cyclosporine, clinically important DDIs are identified. DDIs play a major role in both the production of ADRs and therapeutic failure in the treatment of MTX and specific medications